↑ Rising
Business
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
Roche lung cancer drug extends survival by nearly six months in late-stage trial
Divarasib
2 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Divarasib
This hub groups 2 separate news trends connected to Divarasib, spanning July 2, 2026 through October 26, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 12 article observations and 12 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's KRAS G12C inhibitor, divarasib, outperformed rival therapies in a head-to-head Phase 3 trial for lung cancer.